[
  {
    "ts": null,
    "headline": "Does Charles River’s Lowered Guidance After a Strong Quarter Signal Shifting Priorities for CRL?",
    "summary": "Charles River Laboratories International recently presented at the Jefferies London Healthcare Conference 2025, following the release of its third quarter results that surpassed analyst expectations on revenue and adjusted EPS. Although the company outperformed on quarterly metrics, its decision to lower full-year GAAP EPS guidance has introduced new uncertainty about its near-term outlook. Given the company’s improved adjusted EPS but reduced annual guidance, we’ll explore how these mixed...",
    "url": "https://finnhub.io/api/news?id=fec6f465af311325fa742ac97b85d82019b5e1cf1cf8c96de0426047bdf4fc71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763795418,
      "headline": "Does Charles River’s Lowered Guidance After a Strong Quarter Signal Shifting Priorities for CRL?",
      "id": 137579309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River Laboratories International recently presented at the Jefferies London Healthcare Conference 2025, following the release of its third quarter results that surpassed analyst expectations on revenue and adjusted EPS. Although the company outperformed on quarterly metrics, its decision to lower full-year GAAP EPS guidance has introduced new uncertainty about its near-term outlook. Given the company’s improved adjusted EPS but reduced annual guidance, we’ll explore how these mixed...",
      "url": "https://finnhub.io/api/news?id=fec6f465af311325fa742ac97b85d82019b5e1cf1cf8c96de0426047bdf4fc71"
    }
  }
]